These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32162057)

  • 41. Molecular pathways: CDK4 inhibitors for cancer therapy.
    Dickson MA
    Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
    Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
    Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas.
    Lai S; El-Naggar AK
    Lab Invest; 1999 Mar; 79(3):255-60. PubMed ID: 10092061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study.
    Solomon MC; Vidyasagar MS; Fernandes D; Guddattu V; Mathew M; Shergill AK; Carnelio S; Chandrashekar C
    Med Oncol; 2016 Dec; 33(12):138. PubMed ID: 27817107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
    Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
    Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
    Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
    Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.
    Chaudhary S; Pothuraju R; Rachagani S; Siddiqui JA; Atri P; Mallya K; Nasser MW; Sayed Z; Lyden ER; Smith L; Gupta SD; Ralhan R; Lakshmanan I; Jones DT; Ganti AK; Macha MA; Batra SK
    Cancer Lett; 2021 Jul; 510():79-92. PubMed ID: 33878394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
    Semczuk A; Miturski R; Skomra D; Jakowicki JA
    Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
    Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
    Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors.
    Kovar H; Jug G; Aryee DN; Zoubek A; Ambros P; Gruber B; Windhager R; Gadner H
    Oncogene; 1997 Oct; 15(18):2225-32. PubMed ID: 9393981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
    Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
    Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.